Cedric Francois - 09 Jun 2025 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Chief Executive Officer, Director
Signature: /s/ David Watson, attorney-in-fact for Cedric Francois
Issuer symbol: APLS
Transactions as of: 09 Jun 2025
Net transactions value: +$5,574,625
Form type: 4
Filing time: 11 Jun 2025, 16:21:22 UTC
Previous filing: 30 Jan 2025
Next filing: 16 Jul 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Francois Cedric	Chief Executive Officer, Director	C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM	/s/ David Watson, attorney-in-fact for Cedric Francois	11 Jun 2025	0001658080

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Award	$5,574,625	+287,500		$19.39	287,500	09 Jun 2025	Common Stock	287,500	$19.39	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This represents stock option award granted on June 9, 2025, which will vest over a two-year period. Specifically, 50% of the options will vest on each of the one-year and two-year anniversaries of the grant date, contingent upon continued service.